絞り込み

16645

広告

「抗マラリア薬を治療薬に」中国保健当局専門家チームトップ (NHK)

中国で新型コロナウイルスに感染して死亡した人が1800人を超える中、中国の保健当局の専門家チームのトップは、新型コロナウイルスをめぐって抗マラリア薬が治療に効果...

  1. 咳喘息の考え方と漢方処方 (日経BP)
  2. 不安と焦りを抱えた患者 (日経BP)
  3. 米兵もむせび泣いた硫黄島の激戦、75年前...
  4. 【動画】「cough medicine」...

ニュース一覧

Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors.

著者 Lebreton A , Lapalud P , Chambost H , Biron-Andréani C , Morange PE , Combescure C , Marquès-Verdier A , Berger C , Schved JF , Granier C , Lavigne-Lissalde G
Thromb Haemost.2011 Apr 7 ; 105(6):.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Geraldine Lavigne-Lissalde, UMR 3145 SysDiag CNRS/Bio-Rad, Cap Delta, 1682 rue de la Valsière, CS 61003, 34184 Montpellier, France, Tel.: +33 6 20 89 69 01, Fax: +33 4 67 16 66 01, E-mail: geraldine.lavigne@sysdiag.cnrs.fr.

スターを付ける スターを付ける     (33view , 0users)

Full Text Sources

Medical

Miscellaneous

Antibodies (inhibitors and non-neutralising antibodies [NNA]) directed against factor VIII (FVIII) remain the main iatrogenic complication in haemophilia A (HA) patients. Inhibitors reduce FVIII pro-coagulant properties, whereas NNA are directed against non-functional epitopes. NNA are poorly studied and their prevalence, epitope specificity and physiopathology inadequately defined. The aim of this study was first to evaluate NNA prevalence in a French retrospective multicentric series of 210 patients without inhibitors, then to determine their epitope specificity (against the heavy chain [HC] or the light chain [LC] of FVIII) and particularly to assess the prevalence of anti-B domain NNA using specifically designed x-MAP assays. NNA occurred in 18.1% of patients (38/210) and their prevalence was not influenced by the severity of the disease. Among the 38 patients with NNA, 73.7% had anti-FVIII Abs against the HC, 13.2% against the LC and 13.2% had anti-FVIII Abs against both chains. There is thus a clear immuno-dominance of the HC of FVIII in the epitope profile of NNA, whatever the severity of HA. The proportion of NNA that recognised the B domain was 18.4% (n=7/38). A multivariate analysis did not highlight differences in NNA occurrence between patients treated with recombinant FVIII or with plasma- derived FVIII (19.6% vs. 14.9%, p=0.53).
PMID: 21475776 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード